Asymmetric Hydrogenation

Our collection of proprietary asymmetric hydrogenation catalysts comprises both our own catalyst systems and several powerful in-licensed catalytic technologies. We conduct unbiased screening projects for our customers, accessing our collection of more than 400 preformed catalysts, containing proprietary and non-proprietary technology. In addition, Dowpharma^SM has developed the technologies to enable a secure supply of commercial quantities of ligands and storage-stable pre-catalysts. We have proven these technologies in commercial API manufacturing.

Dowpharma has secured a worldwide exclusive license from DuPont for the DuPhos^TM/BPE family of asymmetric hydrogenation ligands for use in pharmaceutical applications. We have been developing these ligand and catalyst systems since 1995 to broaden both their commercial application and our readiness to use the technology for new opportunities. In addition to the in-licensed systems, we have expanded our range of catalysts to include the FerroTANE™ ligand series, which can give superior results on certain substrate types in comparison to other ligands.

asymmetric hydrogenation

For more information:
Applications of Phosphetane Ligands (246KB PDF)
DuPhos & BPE Technology Exclusive license from DuPont for Pharma (205KB PDF)

asymmetric hydrogenation

Since December 2000, we have licensed from the Japan Science and Technology Corporation the technologies of Professors Noyori and Ikariya for the hydrogenation of ketone functions. With single-isomer chiral ligands, the ruthenium catalysts can be used at exceedingly low loading (e.g. 100,000:1 substrate / catalyst) to deliver high enantiomeric excess secondary alcohols. We found that a particularly valuable ligand in this technology is the bisphosphine PhanePhos, for which Dowpharma has a license from Merck Inc. Furthermore, Dowpharma has its own biaryl ligand HexaPHEMP, which is valuable for these and other related ruthenium-based catalysts.

For more information:
Imines Using Diverse Set of [Diphosphine RuCI2 Diamine] Precatalysts (311KB PDF)
Selective Catalysis for the Hydrogenation of Unfunctionalised Ketones (261KB PDF)
Asymmetric Hydrogenation – Integration with Biocatalysis for the Manufacture of α-Amino Acids (167KB PDF)
Asymmetric Hydrogenation – Selective Catalysts for Transfer Hydrogenation of Ketones and Imines (222KB PDF)
Rapid screening of asymmetric hydrogenation catalysts leading to commercial applications (247KB PDF)

In order to view some information you may need to download Adobe Reader.

^SMService mark of The Dow Chemical Company
™Trademark of DuPont


Capabilities and Services Biocatalysis Biocatalysis Capability Collaborators Enzyme Classes Chemocatalysis Asymmetric Hydrogenation Hydroformylation Trost Allylic Alkylation Complex Synthesis Products Offered Process Development Customer Needs Development Timeline Emerging Pharma Catalyst/Ligand Availability Unnatural Fmoc Amino Acids Unnatural Boc Amino Acids 2-Alkyl Succinates Amines Alcohols Functionalized Cyclopentanes Scaffolds Facilities Literature and Resources Asymmetric Hydrogenation Dowpharma Scientific Publications Hydroformylation Trost Allylic Alkylation Complex Synthesis Biocatalysis Process Development General Publications News Source: Aquapharm Bio-Discovery Ltd Enters a Collaboration Deal with Dowpharma<sup>SM</sup> Contract Manufacturing Services. Dowpharma Relaunches Web Site, Will Make Donation to UNICEF Dow Expands Presence in Pharmaceutical Market, Uniting Existing Offers Under Dowpharma Portfolio Dowpharma Announces New Capabilities in Asymmetric Hydroformylation for Pharmaceutical Applications License of JST Catalyst Technology Expands Dowpharma’s Chiral Commercial Production Capabilities Dowpharma Signs Agreement with Japanese Distributor to Market Pharmaceutical Services in Japan Events Calendar REACH Contact Us	Asymmetric Hydrogenation Our collection of proprietary asymmetric hydrogenation catalysts comprises both our own catalyst systems and several powerful in-licensed catalytic technologies. We conduct unbiased screening projects for our customers, accessing our collection of more than 400 preformed catalysts, containing proprietary and non-proprietary technology. In addition, Dowpharma^SM has developed the technologies to enable a secure supply of commercial quantities of ligands and storage-stable pre-catalysts. We have proven these technologies in commercial API manufacturing. Dowpharma has secured a worldwide exclusive license from DuPont for the DuPhos^TM/BPE family of asymmetric hydrogenation ligands for use in pharmaceutical applications. We have been developing these ligand and catalyst systems since 1995 to broaden both their commercial application and our readiness to use the technology for new opportunities. In addition to the in-licensed systems, we have expanded our range of catalysts to include the FerroTANE™ ligand series, which can give superior results on certain substrate types in comparison to other ligands. For more information: Applications of Phosphetane Ligands (246KB PDF) DuPhos & BPE Technology Exclusive license from DuPont for Pharma (205KB PDF) Since December 2000, we have licensed from the Japan Science and Technology Corporation the technologies of Professors Noyori and Ikariya for the hydrogenation of ketone functions. With single-isomer chiral ligands, the ruthenium catalysts can be used at exceedingly low loading (e.g. 100,000:1 substrate / catalyst) to deliver high enantiomeric excess secondary alcohols. We found that a particularly valuable ligand in this technology is the bisphosphine PhanePhos, for which Dowpharma has a license from Merck Inc. Furthermore, Dowpharma has its own biaryl ligand HexaPHEMP, which is valuable for these and other related ruthenium-based catalysts. For more information: Imines Using Diverse Set of [Diphosphine RuCI2 Diamine] Precatalysts (311KB PDF) Selective Catalysis for the Hydrogenation of Unfunctionalised Ketones (261KB PDF) Asymmetric Hydrogenation – Integration with Biocatalysis for the Manufacture of α-Amino Acids (167KB PDF) Asymmetric Hydrogenation – Selective Catalysts for Transfer Hydrogenation of Ketones and Imines (222KB PDF) Rapid screening of asymmetric hydrogenation catalysts leading to commercial applications (247KB PDF) In order to view some information you may need to download Adobe Reader. ^SMService mark of The Dow Chemical Company ™Trademark of DuPont
	Small Molecules Dow Home Privacy Statement Internet Disclaimer Accessibility Statement Site Map Copyright © The Dow Chemical Company (1995-2008). All Rights Reserved.